SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Jack Colton who wrote (16309)3/10/1999 11:07:00 PM
From: QuietWon  Read Replies (1) | Respond to of 90042
 
IMCL - another way of looking at it- if Genetech able to earn $30 million in first 3 months, did they keep up that pace or was that just ramping up?

Suppose it's flat $30 million revs for at least 4 3-months periods ie. $120 million in the first 12 months the drug is offered.
120/25 total shares about $5 per share in revenue in the first 12 months. Now what is the net margin as % sales - say 25% giving $1.25 per share in earnings oh oh earnings isn't that bad.

So based on the above $1.25 EPS from C225 alone on a best guess estimate. Wonder what that makes the % increase in earnings from one yr to the next - hmmm Comments?



To: Jack Colton who wrote (16309)3/10/1999 11:18:00 PM
From: Mark_H  Read Replies (1) | Respond to of 90042
 
I think in his case, he was doing more than just mentioning a stock. I do agree however, that we all need to think about what we post.



To: Jack Colton who wrote (16309)3/11/1999 2:40:00 PM
From: Moosie  Respond to of 90042
 
Jack T Colton
How do you do that?
Kind of like the way I tune out the mother-in-law
btw, I like the humor, eh

moosie
@859



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News